Nervgen Pharma Corp. has outlined its plans to develop its new drug candidate, NVG-300, with a focus on three initial indications: ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI).
Defence Therapeutics Inc. has demonstrated that its second-generation ARM-X anticancer vaccine is therapeutically effective against pre-established ovarian cancer (ID8 model) when combined with an anti-PD-1 immune checkpoint inhibitor.
CDR-Life Inc. has expanded its pipeline of novel T-cell engagers (TCE) with the addition of CDR-813 and CDR-505. CDR-813 is a highly potent and selective TCE candidate targeting tumors expressing PRAME (preferentially expressed antigen in melanoma) in HLA-A*02:01 patients.
Transmembrane serine protease 6 (TMPRSS6) is a negative regulator of hepcidin, which is the main iron homeostasis-regulating hormone. Regeneron Pharmaceuticals Inc. has recently presented preclinical data for the monoclonal antibody targeting TMPRSS6, REGN-7999, which is being developed for the treatment of iron overload.
Additional early-stage research and drug discovery news in brief, from: Arvinas, Clene, Dyne Therapeutics, Kura Oncology, Mira Pharmaceuticals, Scholar Rock, Turn Therapeutics, Viking Therapeutics.
Sumitomo Pharma America Inc. has patented 2-phenylmorpholine and 2-phenyl(thio)morpholine compounds acting as 5-HT1A and trace amine-associated receptor 1 (TAAR1; TAR1) agonists.
Cerevel Therapeutics Inc. and Pfizer Inc. have jointly developed azaindole compounds acting as phosphodiesterase 4 (PDE4) inhibitors potentially useful for the treatment of psoriasis, atopic dermatitis, idiopathic pulmonary fibrosis, diabetes, sepsis, autoimmune disease, cystic fibrosis and inflammatory bowel disease, among others.
Ranok Therapeutics (Hangzhou) Co. Ltd. has prepared 4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-pyrido[4,3-d]pyrimidine derivatives acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12D mutant) interaction inhibitors and reported to be useful for the treatment of cancer.
RSS
